Evidence map›Paper›PMID 42694073›Full record

ArticlePatient related outcome measures2026

Content validity of the Familial Chylomicronemia Syndrome Symptoms and Impacts Scale (FCS-SIS) for severe hypertriglyceridemia (sHTG).

Asia Sikora Kessler, Tammy Michelle Brown, Bonita Basnyat, Aaron Yarlas, Jennifer Dine

Abstract read
In one paragraph

Article in Patient related outcome measures, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Asia Sikora KesslerHealth Economics & Outcomes Research, Ionis Pharmaceuticals Inc., Carlsbad, CA, US.
Tammy Michelle BrownPatient-Centered Outcomes Assessment, RTI Health Solutions, Durham, NC, US.
Bonita BasnyatPatient-Centered Outcomes Assessment, RTI Health Solutions, Durham, NC, US.
Aaron YarlasHealth Economics & Outcomes Research, Ionis Pharmaceuticals Inc., Carlsbad, CA, US.
Jennifer DinePatient-Centered Outcomes Assessment, RTI Health Solutions, Durham, NC, US.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Severe hypertriglyceridemia (sHTG) and familial chylomicronemia syndrome (FCS) are metabolic conditions associated with an increased risk of adverse health outcomes. The FCS Symptoms and Impacts Scale (FCS-SIS) was developed to assess the symptoms and impacts of FCS. This study assessed the content validity of the 4 FCS-SIS symptom items in adults with sHTG. Methods: Two iterative rounds of qualitative interviews were conducted with adults (aged ≥ 18 years) who had clinician-confirmed sHTG (triglycerides ≥ 500 mg/dL) and recently experienced ≥ 2 symptoms of sHTG. Participants described their initial experiences and symptoms of sHTG during concept elicitation. Cognitive debriefing of the 4 FCS-SIS symptom items assessed relevance, interpretability, answerability, and meaningful change. Results: Among 20 participants, the most frequently reported, most bothersome, and most important-to-treat sHTG symptoms were difficulty thinking (n = 20), physical fatigue (n = 20), diarrhea (n = 19), and abdominal pain (n = 18), which the 4 FCS-SIS symptom items assess. Participants reported these items to be easy to understand (n = 20) and, for most items, reported that a 1- to 2-point improvement would be meaningful. Conclusion: FCS-SIS symptom items are content-valid items for the assessment of sHTG symptoms in adults with sHTG.

Indexed as

content validityfamilial chylomicronemia syndromeFCSFCS-SISSevere hypertriglyceridemiasHTG

Identifiers

PMID42694073
PMCPMC13536960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.